Goldan Keith A. 4

What Happened Keith Goldan, a director of Abeona Therapeutics, received a grant/award of 32,751 restricted common shares on April 1, 2026. The shares were granted at $0.00 per share (total reported value $0). This is an award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: April 1, 2026; Grant type: Award/Grant (Form 4 code A)
• Price: $0.00 per share; Shares acquired: 32,751; Reported total value: $0
• Vesting: All restricted stock will vest on April 1, 2027 (footnote)
• Shares owned after transaction: Not specified in the provided filing
• Filing date: April 7, 2026 — filed six days after the transaction, which is outside the typical 2-business-day reporting window

Context Restricted stock awards to directors are common forms of compensation and do not necessarily indicate a purchase-based bullish signal. The key investor detail here is the vesting date (Apr 1, 2027), which determines when ownership fully transfers and potential sale could occur.